Apotea AB (publ) (CHIX:APOTES) Change In Receivables: kr-33 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:APOTES Apotea AB (publ) CHIX:APOTES
18 GF Score
Price kr65.20
! 1 Warning Sign
View Full Analysis

What is Apotea AB (publ) Change In Receivables?

Apotea AB (publ) CHIX:APOTES 18 Change In Receivables is kr-33 Mil as of Jun. 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Apotea AB (publ)'s change in receivables for the quarter that ended in Jun. 2026 was kr2 Mil. It means Apotea AB (publ)'s Accounts Receivable declined by kr2 Mil from Mar. 2026 to Jun. 2026 .

Apotea AB (publ)'s change in receivables for the fiscal year that ended in Dec. 2025 was kr-11 Mil. It means Apotea AB (publ)'s Accounts Receivable increased by kr11 Mil from Dec. 2024 to Dec. 2025 .

Apotea AB (publ)'s Accounts Receivable for the quarter that ended in Jun. 2026 was kr375 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Apotea AB (publ)'s Days Sales Outstanding for the three months ended in Jun. 2026 was 16.90.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Apotea AB (publ)'s liquidation value for the three months ended in Jun. 2026 was kr-451 Mil.

Apotea AB (publ)  (CHIX:APOTEs) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Apotea AB (publ)'s Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=375.1/2025.9*91
=16.90

2. In Ben Graham's calculation of liquidation value, Apotea AB (publ)'s accounts receivable are only considered to be worth 75% of book value:

Apotea AB (publ)'s liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=103.5-1263+0.75 * 375.1+0.5 * 855.3
=-451

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) Change In Receivables Related Terms

Apotea AB (publ) Change In Receivables Historical Data

* Premium members only.

The historical data trend for Apotea AB (publ)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) Change In Receivables Chart

Apotea AB (publ) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
-20.50 -15.90 -41.70 -80.40 -11.30

Apotea AB (publ) Quarterly Data
Dec21 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.60 -19.30 27.30 -43.00 2.30
CHIX:APOTES
18GF Score
Apotea AB (publ) CHIX:APOTES
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apotea AB (publ) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr-33 Mil mean?
Apotea AB (publ) (CHIX:APOTES) has a Change In Receivables of kr-33 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Apotea AB (publ) and its competitors.
Is Apotea AB (publ)'s Change In Receivables too high?
Apotea AB (publ)'s current Change In Receivables is kr-33 Mil. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Change In Receivables compare to competitors?
Apotea AB (publ)'s Change In Receivables of kr-33 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Apotea AB (publ) and its competitors. Apotea AB (publ)'s current Change In Receivables is kr-33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Change In Receivables of kr-33 Mil. The current Change In Receivables is kr-33 Mil. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Change In Receivables is kr-33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apotea AB (publ) Business Description

Other Exchanges APOTEA:SwedenV30:Germany
Address Sveavagen 168, Stockholm, SWE, 11346
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score

Get the complete analysis for CHIX:APOTES

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr65.20
Price